Depletion of CD4+/CD25high regulatory T cells may enhance or uncover factor VIII‐specific T‐cell responses in healthy individuals

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2007-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1538-7836.2007.02336.xPMID 17155960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human Regulatory T Cells Control Xenogeneic Graft-versus-Host Disease Induced by Autologous T Cells in RAG2−/−γc−/− Immunodeficient Mice

  2006cited by this paper
• Cd4+Cd25+ regulatory T cells and their therapeutic potential.

  2006cited by this paper
• inhibitors for

  2006cited by this paper
• Acquired hemophilia A: A concise review

  2005cited by this paper
• Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.

  2005cited by this paper
• Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

  2005cited by this paper
• Treatment of patients with acquired inhibitors

  2005cited by this paper
• Inhibitors in haemophilia: pathophysiology

  2004cited by this paper
• Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

  2003cited by this paper
• Supporting Online Material

  2003cited by this paper
• Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome

  2002cited by this paper
• Sensitization of CD4+ T Cells to Coagulation Factor VIII: Response in Congenital and Acquired Hemophilia Patients and in Healthy Subjects

  2000cited by this paper
• Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.

  1999cited by this paper
• Central tolerance of T cells.

  1995cited by this paper
• Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

  1994cited by this paper
• Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.

  1992cited by this paper

• Tolerance to Factor VIII in the Era of Non-Factor Therapies: Immunological Perspectives and a Systematic Review of the Literature.

  2025cites this paper
• T cells from individuals with and without hemophilia A respond to the same epitopes in factor VIII.

  2025cites this paper
• Frequency of natural regulatory T cells specific for factor VIII in the peripheral blood of healthy donors

  2024cites this paper
• The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes

  2024influential citation
• Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives.

  2023cites this paper
• Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?

  2022cites this paper
• [Therapeutic applications of extracellular vesicles].

  2021cites this paper
• Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach

  2021cites this paper
• Les atteintes neurologiques liées au SARS-CoV-2 et autres coronavirus humains

  2020cites this paper
• La puissance de calcul des dendrites du cortex cérébral humain

  2020cites this paper
• Inhibitors—Recent insights

  2020cites this paper
• [Origin and nature of the neutralizing immune response against therapeutic factor VIII].

  2020cites this paper
• Tolerating Factor VIII: Recent Progress

  2020cites this paper
• [Caspase inhibition: From cellular biology and thanatology to potential clinical agents].

  2020cites this paper
• In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity

  2019cites this paper
• Activation of CD4 and CD8 T cell receptors and regulatory T cells in response to human proteins

  2018cites this paper
• Review of immune tolerance induction in hemophilia A.

  2018cites this paper
• Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity

  2018cites this paper
• Immunogenic Determinants of Coagulation Factor VIII

  2018cites this paper
• Challenges related to the immunogenicity of parenteral recombinant proteins: Underlying mechanisms and new approaches to overcome it

  2018cites this paper
• Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

  2018cites this paper
• Investigating the IGSF2 and TNFα Genes Polymorphism and the Risk of Inhibitor Development in Patients with Hemophilia A

  2018cites this paper
• Regulatory T cells and their potential for tolerance induction in haemophilia A patients

  2016cites this paper
• Achievements, challenges and unmet needs for haemophilia patients with inhibitors

  2016cites this paper
• Assessment of the frequency of regulatory T cells (CD4+CD25+CD127−) in children with hemophilia A: relation to factor VIII inhibitors and disease severity

  2016cites this paper
• Short title: Promiscuity of factor VIII

  2016cites this paper
• Adeno-Associated Viral Vector-Driven Expression of Coagulation Proteins for Treatment of Hemophilias and Cancer

  2015cites this paper
• In silico calculated affinity of FVIII‐derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene

  2014cites this paper
• T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.

  2013influential citation
• Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A?

  2012cites this paper
• Les signaux de danger dans l'initiation de la réponse immunitaire contre le facteur VIII thérapeutique

  2012cites this paper
• Immunogenicity to Biologics: Mechanisms, Prediction and Reduction

  2012cites this paper
• [Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia].

  2011cites this paper
• The etiology of inhibitor development in children with severe hemophilia A

  2011cites this paper
• Naturally occurring CD4+ CD25+ cells in modulating immune response to administered coagulation factor VIII in factor VIII‐deficient mice

  2011cites this paper
• Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII‐specific T cells

  2011cites this paper
• HLA‐DR‐restricted T‐cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P

  2010cites this paper
• B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses

  2009cites this paper
• Role of regulatory T cells in tolerance to coagulation factors

  2009cites this paper
• A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A

  2009cites this paper
• Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A.

  2008cites this paper
• FVIII Immunity: Early Events and Tolerance Mechanisms to FVIII

  2008cites this paper
• Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells

  2008cites this paper
• T‐cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self‐peptide

  2007cites this paper
• Immunogenicity of protein therapeutics.

  2007cites this paper
• A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes

  2007cites this paper